People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AxoSim, Inc. | — | Biotechnology | Series A | $17.4M | $22.3M | 2024 |
David Weiner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Weiner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Moore | 1 | 12 |
| Michael Katz | 1 | 6 |
| Jeffrey Silverman | 1 | 4 |
| Dale Pfost | 1 | 3 |
| Miklos Kobor | 1 | 3 |
| Benjamin Cappiello | 1 | 2 |
| Alif Saleh | 1 | 2 |
| J. Lowry Curley | 1 | 1 |
| Monica Metea | 1 | 1 |
| Thomas Hartung | 1 | 1 |
| Lowry Curley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.